Organization
University of Chicago Medical Center, Chicago, IL
41 abstracts
Abstract
SWOG S1011: A phase III surgical trial to evaluate the benefit of a standard versus an extended lymphadenectomy performed at time of radical cystectomy for muscle invasive urothelial cancer.Org: UT Health San Antonio, San Antonio, TX, The Ohio State University, Columbus, OH, USC/Norris Comprehensive Cancer Center, Los Angeles, CA, University of Chicago Medical Center, Chicago, IL, SWOG Cancer Research Network, San Antonio, TX,
Abstract
Neoadjuvant nivolumab, paclitaxel, and carboplatin followed by response-stratified chemoradiation in locoregionally advanced HPV negative head and neck squamous cell carcinoma (HNSCC): The DEPEND trial.Org: University of Chicago Department of Surgery, University of Chicago Medical Center, Chicago, IL, Department of Medicine, University of Chicago, Department of Radiation and Cellular Oncology, Rush University Medical Center,
Abstract
Lisocabtagene maraleucel (liso-cel) in R/R chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL): Primary analysis of TRANSCEND CLL 004.Org: Fred Hutchinson Cancer Center, Duke University Health System, Center for Lymphoma, University of Chicago Medical Center, Chicago, IL, Banner MD Anderson Cancer Center,
Abstract
Polygenic risk score calibration and association with breast cancer in diverse ancestries.Org: Myriad Genetics, Inc., Vanderbilt University Medical Center, Abramson Cancer Center, University of Pennsylvania, Providence Health/St John Cancer Institute, Memorial Sloan Kettering Cancer Center,
Abstract
Clinical and analytical validation of a targeted gene expression biomarker predicting meningioma outcomes and radiotherapy responses.Org: University of California-San Francisco, University of Chicago Medical Center, Chicago, IL, University of California San Francisco, University Clinic of Heidelberg, UCSF Department of Radiation Oncology,
Abstract
NRG-LU002: Randomized phase II/III trial of maintenance systemic therapy versus local consolidative therapy (LCT) plus maintenance systemic therapy for limited metastatic non-small cell lung cancer (NSCLC).Org: Memorial Sloan Kettering Cancer Center, NRG Oncology Statistics and Data Management Center, American College of Radiology, Philadelphia, PA, University of Texas Southwestern Medical Center at Dallas, Dallas, TX, Washington University School of Medicine in St. Louis, Washington University School of Medicine,
Abstract
Efficacy and safety of entrectinib in children with extracranial solid or primary central nervous system (CNS) tumors harboring NTRK or ROS1 fusions.Org: Roche Products Ltd., Genentech, Memorial Sloan Kettering Cancer Center, Hopp Children’s Cancer Center Heidelberg (KiTZ), Fondazione IRCCS Istituto Nazionale dei Tumori di Milano,
Abstract
A pilot study of post-consolidation chemoimmunotherapy for high-risk neuroblastoma (ANBL19P1): A report from the Children’s Oncology Group.Org: University of Chicago Medical Center, Chicago, IL, Children's Oncology Group Statistics and Data Center, University of Florida, University of Florida-Health Cancer Center, Orlando Health, Orlando, FL, Children's Oncology Group Statistics & Data Center, Department of Biostatistics & Data Science,
Abstract
Discontinuation of maintenance therapy in multiple myeloma guided by multimodal measurable residual disease negativity (MRD2STOP).Org: University of Chicago, Department of Medicine, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA, University of Chicago Medical Center, Chicago, IL, Division of Hematology and Medical Oncology, University of Colorado School of Medicine,
Abstract
I-SPY2 Endocrine Optimization Pilot (EOP): Neoadjuvant amcenestrant +/- abemaciclib +/- letrozole in molecularly selected patients (pts) with HR+ HER2- stage 2/3 breast cancer (BC).Org: University of California, San Francisco, Mayo Clinic, University of Chicago Medical Center, Chicago, IL, Winship Cancer Institute of Emory University, Hunstman Cancer Institute at the University of Utah,
Abstract
Rapid survey assessment: Barriers and facilitators to mammogram completion in English and Spanish-speaking patients in a federally qualified health center (FQHC) setting.Org: University of Chicago, Tapestery 360, University of Chicago Medical Center, Chicago, IL,
Abstract
Identifying eligibility criteria that perpetuate race/ethnic disparities in acute myeloid leukemia (AML) clinical trial participation.Org: Dana-Farber Cancer Institute, University of Chicago Medicine, University of Chicago Medical Center, Chicago, IL, University of Chicago, University of Illinois at Chicago,
Abstract
Impact of late immune effector cell associated hematotoxicity (ICAHT) and prolonged neutropenia after CAR-T therapy on infection and survival outcomes.Org: Vanderbilt University Medical Center, Memorial Sloan Kettering Cancer Center, Oregon Health & Science University, University of Pennsylvania, University of Kansas Medical Center, Department of Biostatistics & Data Science,
Abstract
Hematology/oncology clinical investigator training: Is current model of education adequate?Org: University of Chicago, Loyola University Maryland, University of Colorado School of Medicine, University of Chicago Medical Center, Chicago, IL,
Abstract
Evaluation of cyclin-dependent kinase 4/6 inhibitor-induced serum creatinine elevations in patients with hormone receptor positive breast cancer.Org: University of Chicago Medicine, University of Chicago, University of Chicago Medical Center, Chicago, IL,
Abstract
Interpretable artificial intelligence-based analysis for morphologic classification of neuroblastic tumors.Org: University of Chicago Pritzker School of Medicine, Children's Hospital of Philadelphia, University of Chicago, Section of Hematology/Oncology, Department of Medicine, University of Chicago, Chicago, IL, Stanford University Medical Center, Stanford, CA,
Abstract
Evolving adjuvant estrogen therapy prescribing among breast oncology workforce.Org: University of Chicago, University of Chicago Medical Center, Chicago, IL, Section of Urology, Department of Surgery, Brigham and Women's Hospital, Boston, MA, University of Chicago Department of Urology,
Abstract
Global adoption of remote technologies to enable patient-centric oncology clinical trials: Analysis by the Bloomberg New Economy International Cancer Coalition.Org: Memorial Sloan Kettering Cancer Center, Johns Hopkins University Bloomberg School of Public Health, Princess Margaret - University Health Network, University of Chicago Medical Center, Chicago, IL, United States Food and Drug Administration,
Abstract
Phase II study of pembrolizumab plus mifepristone in patients with advanced HER2-negative breast cancer.Org: University of Chicago, University of Chicago Medicine, Northshore University Health System, University of Chicago Medical Center, Chicago, IL, Section of Hematology/Oncology,
Abstract
Comparing the impact of steroid sparing immunosuppression vs. steroid monotherapy for immune-related adverse events in non–small cell lung cancer and melanoma.Org: University of Chicago Medical Center, Chicago, IL, Department of Medicine, Icahn School of Medicine at Mount Sinai, Division of Hematology-Oncology, Department of Medicine, Seoul Medical Center, Seo-Gu, South Korea, University of Chicago Center for Health and The Social Sciences, University of Chicago,
Abstract
Outcomes among adult recipients of CD19 CAR T-cell therapy for Burkitt lymphoma.Org: Fred Hutchinson Cancer Research Center, Boston University Medical Center, Massachusetts General Hospital, Dana-Farber Cancer Institute, Medical College of Wisconsin,
Abstract
The impact of circulating tumor cell HOXB13 RNA detection in men with metastatic castrate-resistant prostate cancer (mCRPC) treated with abiraterone or enzalutamide.Org: Duke University School of Medicine, Department of Head and Neck Surgery & Communication Sciences, Durham, NC, NewYork-Presbyterian/Weill Cornell Medical Center, Duke Cancer Institute, University of Minnesota Masonic Cancer Center, Minneapolis, MN, Memorial Sloan Kettering Cancer Center,
Abstract
Treatment outcomes in patients with discordant recurrence score and RSClin risk predictions.Org: University of Chicago, University of Chicago Medical Center, Chicago, IL, University of Chicago Department of Public Health Sciences, Center for Data Intensive Science at the University of Chicago, Department of Medicine, University of Chicago,
Abstract
Multi-institutional study evaluating the role of circulating tumor DNA (ctDNA) in management of appendiceal cancers (AC).Org: University of Chicago Medical Center, Chicago, IL, Chicago, IL, Il-Yang Pharmaceuticals, Department of Surgery, Brigham and Women's Hospital, Boston, MA, Section of Surgical Oncology,
Abstract
Alliance A021806: A phase III trial evaluating perioperative versus adjuvant therapy for resectable pancreatic cancer.Org: Northwestern University Robert H. Lurie Comprehensive Cancer Center, Alliance Statistics and Data Center, Mayo Clinic, University of California San Francisco, Helen Diller Family Comprehensive Cancer Center,
Abstract
Alliance A022104/NRG-GI010: A randomized phase II trial testing the efficacy of triplet versus doublet chemotherapy to achieve clinical complete response in patients with locally advanced rectal cancer—The Janus Rectal Cancer trial.Org: Memorial Sloan Kettering Cancer Center, The University of Texas MD Anderson Cancer Center, Stem Cell Transplantation Rsch, Houston, TX, Alliance Statistics and Data Center, Mayo Clinic, University of North Carolina at Chapel Hill,
Abstract
Randomized phase I/II trial of TheraT vectors expressing HPV16 specific antigens with neoadjuvant chemotherapy followed by transoral robotic surgery (TORS) or risk/response stratified chemoradiotherapy (CRT) for locoregional HPV16+ oropharyngeal cancer (OPC).Org: Department of Medicine, Icahn School of Medicine at Mount Sinai, University of Chicago, The University of Chicago Medicine Center for Advanced Care at Orland Park, University of Chicago Medical Center, Chicago, IL,
Abstract
Phase I trial of enzalutamide (Enz) plus the glucocorticoid receptor antagonist relacorilant (Rela) for patients with metastatic castration resistant prostate cancer.Org: University of Chicago Medical Center, Chicago, IL, Chicago, IL, Northwestern Medicine Cancer Center Warrenville, University of Chicago, The University of Chicago Medicine Center for Advanced Care at Orland Park,
Abstract
A phase I study of MEK inhibitor selumetinib in combination with azacitidine in patients with higher-risk chronic myeloid neoplasia.Org: University of Chicago, University of Chicago Medical Center, Chicago, IL, University of Michigan, Section of Hematology/Oncology, Department of Medicine, University of Chicago,
Abstract
Dares: A phase II trial of durvalumab and ablative radiation in extensive stage small cell lung cancer.Org: University of Chicago Medical Center, Chicago, IL, University of Kansas Medical Center, Department of Biostatistics & Data Science, University of Kansas Medical Center (KUMC), Northwestern University, Feinberg School of Medicine, Robert H. Lurie Comprehensive Cancer Center, University of Chicago,
Abstract
Longitudinal changes in echocardiographic variables and endothelial function to predict cardiovascular toxicities in patients with multiple myeloma receiving carfilzomib.Org: University of Chicago, University of Chicago Medical Center, Chicago, IL,
Abstract
Incidence of infusion related reactions of daratumumab-hyaluronidase-fihj: Pre-post intervention study of premedication omission.Org: University of Chicago Medical Center, Chicago, IL, Center for Data Intensive Science at the University of Chicago, University of Chicago,
Abstract
Phase 2 randomized trial of neoadjuvant or palliative chemotherapy with or without immunotherapy for peritoneal mesothelioma (Alliance A092001).Org: Mayo Clinic, Alliance Statistics and Data Management Center, Mayo Clinic Arizona, Phoenix, AZ, University of Pittsburgh Medical Center, Johns Hopkins Medicine,
Abstract
Tissue and plasma-based mechanisms of resistance to first-line osimertinib in EGFR-mutant NSCLC: A multi-institutional cohort.Org: Massachusetts General Hospital, Harvard Medical School, Boston, MA, Columbia University Irving Medical Center, New York, NY, USA, New York, NY,
Abstract
Updated results of the phase 1 I-FLOAT trial: Safety and efficacy of combining genotype-guided irinotecan with 5FU, leucovorin, oxaliplatin and docetaxel (gFOLFOXIRITAX) in advanced upper GI cancers.Org: University of Chicago Medical Center, Chicago, IL, University of Chicago, Department of Medicine, Icahn School of Medicine at Mount Sinai, Section of Hematology & Oncology, University of Illinois Chicago,
Abstract
Epidemiology and outcomes of anorectal melanomas: A national database analysis.Org: Ascension Providence Hospital, University of Chicago Medical Center, Chicago, IL, Providence Hospital, Department of Breast Medical Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, China, Newland Medical Associates, P.C.,
Abstract
Changing survival of intrahepatic cholangiocarcinoma based on Surveillance, Epidemiology, and End Results Database (2000–2018).Org: Ascension Providence Hospital, Providence Hospital, Newland Medical Associates, P.C., Department of Breast Medical Oncology, Fujian Cancer Hospital, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Science, Jinan, Shandong, China,
Abstract
A randomized phase II trial of nab-paclitaxel with or without mifepristone for advanced triple-negative breast cancer.Org: University of Chicago, Northshore University Health System, Froedtert & Medical College of Wisconsin, University of Chicago Medical Center, Chicago, IL, Section of Hematology/Oncology,
Abstract
RAMP 202: A phase 2 study of avutometinib (VS-6766) ± defactinib, in patients with advanced KRAS G12V mutant non–small cell lung cancer (NSCLC).Org: Lombardi Comprehensive Cancer Center, Georgetown University Medical School, Washington, DC, Florida Cancer Specialists/Sarah Cannon Research Institute, Sarasota, FL, Lecanto, FL,
Abstract
Introducing yttrium-90 radioembolization to atezolizumab and bevacizumab regimen for intermediate and advanced stage hepatocellular carcinoma: A preliminary report of safety and effectiveness.Org: University of Chicago Medical Center, Chicago, IL, Chicago, IL, Ascension Providence Hospital, Southfield, MI, University of Chicago,
Abstract
A CBTH intervention for reducing stress in women with high risk in a DCE-MRI breast cancer screening study.Org: University of Chicago Pritzker School of Medicine, University of Chicago Medical Center, Chicago, IL, University of Chicago, Department of Obstetrics and Gynecology, Peking Union Medical College Hospital, Beijing, China,